On July 20, WuXi AppTec rose 3.14% in regular trading, trading at 158.8 HKD/share, with turnover of HKD 356 million.

On the news front, multiple international investment banks have recently issued bullish upgrades in quick succession, forming a strong consensus. UBS raised WuXi AppTec's target price to 176.5 HKD and named it a sector top pick; Daiwa significantly lifted its target to 190 HKD; Morgan Stanley raised its target to 168 HKD and reiterated the stock as its preferred name, forecasting a 16% adjusted earnings CAGR from 2025 to 2028. The CXO sector is experiencing a broad recovery supported by strong order momentum, with first-quarter new orders posting substantial growth and backlog rising approximately 40.9% year-over-year.

Within the Life Sciences Tools and Services sector, peers rallied in tandem: Pharmaron up 6.29%, JOINN up 6.06%, WuXi XDC up 5.53%, Insilico up 4.95%, and WuXi Biologics up 4.6%, reflecting a pronounced sector-wide linkage effect.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)